| 前收市價 | 3.7900 |
| 開市 | 3.1800 |
| 買盤 | 2.8000 |
| 賣出價 | 3.2000 |
| 拍板 | 150.00 |
| 到期日 | 2024-08-16 |
| 今日波幅 | 2.3000 - 3.4500 |
| 合同範圍 | 無 |
| 成交量 | |
| 未平倉合約 | 無 |
鉅亨網減肥神藥成分「司美格魯肽」恐致失明！諾和諾德跌近3%
外電周三 (3 日) 報導，國際知名醫學期刊《美國醫學會雜誌》眼科子刊《JAMA Ophthalmology》研究稱，服用司美格魯肽 (semaglutide) 與罹患「非動脈炎性前部缺血性視神經病變」(NAION)間存在相關性。
Investor's Business DailyNovo, Lilly Tumble After Study Ties Blindness Disorder To Weight-Loss Drugs
Novo Nordisk stock skidded Wednesday after a new study suggests its diabetes and weight-loss drug can lead to a blindness-causing disease.
BenzingaUsing Obesity Drugs? Potential Vision Loss Disorder Linked To Novo Nordisk's Ozempic And Wegovy, Study Finds
A new observational study has identified a potential link between Novo Nordisk A/S’s (NYSE:NVO) GLP-1 drugs, Ozempic and Wegovy (semaglutide), and a serious eye condition known as nonarteritic anterior ischemic optic neuropathy (NAION), which can lead to vision loss. NAION refers to a loss of blood flow to the optic nerve (the cable that connects the eye to the brain). This condition typically causes sudden vision loss in one eye without any pain. Also Read: Joe Biden Suggests Novo Nordisk, Eli
